Observational study on biliary tract cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

BABEL is an observational, single-center, prospective study focusing on patients with biliary tract cancers treated at the Medical Oncology Unit of the FPUAG - IRCCS. The study aims to associate overall survival of these patients with IDH1/2 mutations, confirming their prognostic role in both metastatic and resectable disease settings. Additionally, it seeks to correlate FGFR mutations with overall survival and identify new clinical and molecular characteristics linked to treatment response. The study includes both a historical cohort and a prospective cohort for comprehensive analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with biliary tract cancer;
* Patients with radiological evident disease;
* Patients \>18 anni;
* Written informed consent;
* Patients with at least one oncological visit.

Exclusion Criteria:

* Patients without available clinical data;
* Patients without histological diagnosis of BTC;
* Patients without written informed consent.

Where it's running

• Fondazione Policlinico Universitario Agostino Gemelli/IRCSS - UOC di Oncologia Medica
  Roma, Rome, Italy Recruiting

Study contacts

• Principal investigator: Lisa Salvatore, MD, PhD — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: Lisa Salvatore, MD, PhD
• Email: lisa.salvatore@policlinicogemelli.it
• Phone: 0630156318

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sintilimab with NALIRIFOX or GP as first-line treatment for metastatic biliary tract cancer

  This study tests whether adding sintilimab to either NALIRIFOX or gemcitabine‑cisplatin can help people with metastatic biliary tract cancer who have not had prior systemic therapy.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07831993

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Liposomal irinotecan with 5-FU/LV and sintilimab plus SBRT for unresectable biliary tract cancer

  This trial tests whether combining liposomal irinotecan, 5-FU/LV, and sintilimab, followed by SBRT, can help patients with unresectable locally advanced biliary tract cancer become eligible for surgery or slow disease progression.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07797816

• Futibatinib and immunotherapy with chemo as first-line treatment for advanced biliary tract cancer

  A first-line treatment test combines Futibatinib with Zimberelimab and Gemcitabine/Cisplatin to see if it improves survival in people with unresectable or advanced biliary tract cancer.

  Recruiting at 4 sites Phase 3 Taiho Pharmaceutical Co., Ltd. · Brisbane and 20 other locations · NCT07710885

• ctDNA-guided precision care for lung, GIST, colorectal, biliary, and ovarian cancers

  This trial tests a blood test that looks for tumor DNA in patients with several cancers to help guide personalized treatment decisions.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07673861

• Dual-target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

  This trial tests a ready-to-use CAR-NK cell therapy that targets HER2 and CEACAM5 in adults with unresectable or metastatic biliary tract cancers after standard therapy to see if it can help control the disease.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07641036

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.